Home >> Proteins >> Viral Antigens

Viral Antigens(病毒抗原)

A viral Antigen is an antigen with multiple antigenicities that is protein in nature, strain-specific, and closely associated with the virus particle. A viral antigen is a protein encoded by the viral genome.A viral protein is an antigen specified by the viral genome that can be detected by a specific immunological response.

Viruses are infectious pathogens that cause serious diseases & major threats for global public health, such as influenza, hepatitis, & AIDS. Virus is a sub-micrometer particle that has DNA or RNA packed in a shell called capsid. Viral antigens protrude from the capsid and often fulfill important function in docking to the host cell, fusion, and injection of viral DNA/RNA. Antibody-based immune responses form a first layer of protection of the host from viral infection; however, in many cases a vigorous cellular immune response mediated by T-cells and NK-cells is required for effective viral clearance. When cellular immunity is unable to clear the virus, the infection can become chronic, and serum antibodies to the viral pathogen are used as first indicator for the diagnosis of the disease.

ELISAs provide a valuable tool in the detection and diagnosis of virus infection. The ability to produce recombinant viral proteins will ensure that future ELISAs are safe, specific and rapid. Even when a virus cannot be cultured, provided gene sequence is available, it is possible to rapidly respond to emerging viruses and new viral strains of existing pathogens.

Recombinant viral antigens contain part of viral sequence meaning that the recombinant antigen contains a region which can be recognized by different antibodies produced by different individuals. This reduces the risk of false negatives which can occur with synthetic peptides, which contain only a small portion of the entire protein. If an individual infected with a viral antigen makes antibodies to a part of the protein not included in the synthetic peptides, a false negative results.

Recombinant viral protein usually contains a fusion protein/partner which produces superior attachment to assay surfaces such as wells. For this reason, smaller amounts of recombinant protein will produce the same results as larger amounts of unfused protein. The choice of fusion partner prevents false positives, allowing superior adhesion without incorrect results.

Recombinant Viral proteins are expressed in bacteria, yeast, mammalian cells, and viruses. E. Coli cells were first to be used for this purpose but the expressed proteins were not glycosylated, which was a major drawback since many of the immunogenic proteins of viruses such as the envelope glycoproteins, were glycosylated. Nevertheless, in many instances, it was demonstrated that the non-glycosylated protein backbone was just as immunogenic. The obvious advantage of recombinant viral antigens is that they are available in unlimited quantities and the production and quality control processes is simple.

Advantages of defined using recombinant viral antigens:
1. Production and quality control is simple.
2. No nucleic acids or other viral or external proteins, therefore less toxic.
3. Safer in cases where viruses are oncogenic or establish a persistent infection.
4. Feasible even if virus cannot be cultivated

Disadvantages:
1. May be less immunogenic than conventional inactivated whole-virus vaccines.
2. Requires adjuvant .
3. Fails to elicit CMI.

Facts about Viral Antigens:
1. A Viral Protein Mimics its Way into cells.
2. Viral Protein Helps Infected T Cells Stick To Uninfected Cells.
3. The Viral Protein A238L Inhibits Cyclooxygenase-2 Expression through a Nuclear Factor of Activated T Cell-dependent Trans-activation Pathway.
4. Viral Protein is an effective preventative against ear infection.
5. HIV-1 Viral Protein R Induces Apoptosis via a Direct Effect on the Mitochondrial Permeability Transition Pore.
6. The Level of Viral Antigen Presented by Hepatocytes Influences CD8 T-Cell Function.
7. Antigen-presenting cells from calves persistently infected with bovine viral diarrhea virus, a member of the Flaviviridae, are not compromised in their ability to present viral antigen.
8. There is a difference in the distribution and spread of a viral antigen, development of lesions and correlation between presence of viral antigen and lesions.
9. The absence of viral antigens on the surface of equine herpesvirus-1-infected peripheral blood mononuclear cells is a strategy to avoid complement-mediated lysis.
10. Viral Protein Influences Key Cell-signaling Pathway.
11. A viral protein produced by cancer-causing virus influences a key signaling pathway in the immune cells that the virus infects. This stimulates the cells to divide, helping the virus spread through the body.
12. Protection by recombinant viral proteins against a respiratory virulent avian metapneumovirus has been achieved.
13. Viral O-acetylesterases are found in influenza C viruses and Corona-viruses. Viral O-acetylesterases remove cellular receptors from the surface of target cells which destroys the receptor. Recombinant viral O-acetylesterases derived from Sf9 insect cells as chimeric proteins fused to eGFP specifically hydrolyze 9-O-acetylated sialic acids, while that of sialodacryoadenitis virus, a rat coronavirus related to mouse hepatitis virus, is specific for 4-O-acetylated sialic acid. The recombinant esterases were shown to specifically de-O-acetylate sialic acids on glycoconjugates. The recombinant viral proteins can be used to unambiguously identify O-acetylated acids.

Products for  Viral Antigens

  1. Cat.No. 产品名称 Information
  2. GP25461 Rubella E1 Rubella Virus E1 Mosaic Recombinant
  3. GP25462 Rubella E2 Rubella Virus E2 Recombinant
  4. GP25201 S.Typhi H Salmonella Typhi H Antigen Recombinant
  5. GP25204 S.Typhi HylE Salmonella Typhi Haemolysin E Recombinant
  6. GP25202 S.Typhi OMP Salmonella Typhi Outer Membrane Protein Recombinant
  7. GP25203 S.Typhi OMP 52kDa Salmonella Typhi Outer Membrane Protein 52kDa Recombinant
  8. GC70228 SAMT-247 SAMT-247是一种杀微生物剂,可选择性地使病毒核衣壳蛋白NCp7失活,引起锌的排出并阻止RNA的衣壳化。
  9. GC41626 Sappanone A Sappanone A是一种具有较强抗氧化和抗炎活性的同型异黄酮。
  10. GP25167 SARS Core (1-49) SARS-Associated Coronavirus Nucleocapsid Core Recombinant, 1-49 a.a.
  11. GP25168 SARS Core (1-49,192-220 a.a.) SARS-Associated Coronavirus Nucleocapsid Core Recombinant
  12. GP25166 SARS Core (340-390) SARS-Associated Coronavirus Nucleocapsid Core Recombinant, (340-390 a.a)
  13. GP25171 SARS Envelope SARS相关冠状病毒包膜重组体
  14. GP26377 SARS Envelope, His The E
  15. GP25170 SARS Matrix SARS-Associated Coronavirus Matrix Recombinant
  16. GP26380 SARS Membrane The E
  17. GP25173 SARS MERS SARS MERS Spike S1 Recombinant
  18. GP26374 SARS MERS RBD SARS MERS RBD Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 258 amino acids (358-606 aa) and having a molecular mass of 28
  19. GP26373 SARS MERS S2 SARS MERS S2 Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 554 amino acids (752-1296aa) and having a molecular mass of 60
  20. GP26372 SARS MERS, (18-751) SARS MERS Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 740 amino acids (18-751aa) and having a molecular mass of 82
  21. GP26370 SARS MERS, HEK The HEK293 derived recombinant protein contains the SARS MERS Spike Glycoprotein S1, amino acids 18-725 fused to dimeric Fc tag at N-terminal having a total Mw of 215
  22. GP26371 SARS MERS, Sf9 SARS MERS Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 1285 amino acids (18-1296aa) and having a molecular mass of 141
  23. GP25165 SARS Mosaic S(C) SARS-Associated Coronavirus Spike Mosaic S(C) Recombinant
  24. GP25164 SARS Mosaic S(M) SARS-Associated Coronavirus Spike Mosaic S (M) Recombinant
  25. GP25163 SARS Mosaic S(N) SARS-Associated Coronavirus Spike Mosaic S (N) Recombinant
  26. GP26379 SARS Nucleocapsid (340-390), His The E
  27. GP26378 SARS Nucleocapsid, 1-49 a.a. The E
  28. GP26369 SARS Nucleocaspid (2-422), HEK The HEK293 derived recombinant protein contains the SARS Coronavirus Nucleoprotein, amino acids 2-422 fused to a 6 His tag at N-terminal
  29. GP26381 SARS Spike (1-53, 90-115, 171-205) The E
  30. GP26384 SARS Spike (1-666) The HEK293 derived recombinant protein contains the SARS Coronavirus Spike S1 Gycoprotein, amino acids 1-666 fused to His tag at C-terminal
  31. GP26389 SARS Spike (14-1195) SARS Spike produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 1188 amino acids (14-1195 aa) and having a molecular mass of 131
  32. GP26385 SARS Spike (14-667) The HEK293 derived recombinant protein contains the SARS Coronavirus Spike S1 Gycoprotein, amino acids 14-667 fused to His tag at C-terminal
  33. GP26387 SARS Spike (306-515) The recombinant SARS Spike containing a total of 220 amino acids (306-515) and having a calculated Mw of 24
  34. GP26388 SARS Spike (306-515), Sf9 SARS Spike produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 219 amino acids (306-515 aa) and having a molecular mass of 24
  35. GP26386 SARS Spike (306-527) The HEK293 derived recombinant protein contains the SARS Coronavirus spike S glycoprotein Receptor Binding Domain, amino acids 306-527 fused to His tag at C-terminal
  36. GP26382 SARS Spike (408-470, 540-573) The E
  37. GP26383 SARS Spike Mosaic The E
  38. GP25169 SARS-CoV SARS-CoV Nucleocapsid (422a.a) Recombinant
  39. GC39642 SARS-CoV-IN-2 SARS-CoV-IN-2 是一种有效的 SARS-CoV 复制抑制剂。在 Vero 细胞中,SARS-CoV-IN 1 抗冠状病毒,EC50 为 1.9 μM。SARS-CoV-IN-2 抑制 P. falciparum 3D7 和 W2 株,IC50 分别为 21.5 和 30 nM;IC90 分别为 51.0 和 99.9 nM。在 MT-4 细胞中,SARS-CoV-IN-2 降低 HIV-1 诱导的细胞病变,EC50 为 2.9 μM。具有抗疟和抗病毒活性。
  40. GC39563 SARS-CoV-IN-3 SARS-CoV-IN-3 是一种有效的 SARS-CoV 复制抑制剂。在 Vero 细胞中,SARS-CoV-IN-3 抗冠状病毒,EC50 为 3.6 μM。SARS-CoV-IN-3 抑制 P. falciparum 3D7 和 W2 株,IC50 分别为 11.7 和 20.4 nM; IC90 分别为 29.19 和 56 nM。在 MT-4 细胞中,SARS-CoV-IN-3 降低 HIV-1 诱导的细胞病变,EC50 为 10 μM。具有抗疟和抗病毒活性。
  41. GC74628 Semzuvolimab

    UB421

    Semzuvolimab是一种小鼠IgG1κ抗体,靶向p55,T细胞表面抗原T4/Leu-3(CD4)。
  42. GP25161 Shiga Like Toxin 1 Shiga Like Toxin-1 Subunit B Recombinant
  43. GP25162 Shiga Like Toxin 2 志贺样毒素 2 亚基 B 重组体
  44. GP26443 SIV GAG SIV GAG Recombinant produced in E
  45. GP25430 SIV p55 SIV p55 Recombinant
  46. GC61284 Soyasaponin II

    大豆皂苷II

    SoyasaponinII是具有抗病毒活性的皂苷。SoyasaponinII抑制HSV-1,HCMV,流感病毒和HIV-1的复制。SoyasaponinII对HSV-1复制显示出有效的抑制作用。SoyasaponinII作为YB-1磷酸化和NLRP3炎性小体引发的抑制剂,可保护小鼠免受LPS/GalN诱导的急性肝衰竭。
  47. GC60344 Sparstolonin B An isocoumarin with diverse biological activities
  48. GC48101 SSAA09E1 A SARS-CoV entry inhibitor
  49. GC40859 Steffimycin B

    司替霉素B

    An anthracycline bacterial metabolite
  50. GC45570 STING Agonist C11 An agonist of the STING pathway
  51. GC52174 Sulfadoxin-d4

    磺胺邻二甲氧嘧啶-D4,Sulphadoxine-d4

    An internal standard for the quantification of sulfadoxin

Items 601 to 650 of 718 total

per page

Set Descending Direction